STOCK TITAN
  1. Home
  2. News
  3. OCUP

Ocuphire Pharma Inc - OCUP STOCK NEWS

IMPACT
SENTIMENT
OCUP : Nasdaq
Ocuphire Pharma to Present at Euretina and Retina Society Conferences in October
conferences
IMPACT
SENTIMENT
OCUP : Nasdaq
Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents
fda approval
IMPACT
SENTIMENT
OCUP : Nasdaq
Ocuphire Pharma to Participate in Three Upcoming Investment Bank Conferences
conferences
IMPACT
SENTIMENT
OCUP : Nasdaq
Ocuphire Pharma to Present at ESCRS 2023 and MODLive! Conferences in September
conferences
IMPACT
SENTIMENT
OCUP : Nasdaq
Abstract on ZETA-1 Study of APX3330 Receives Award at Women in Ophthalmology (WIO) Summer Symposium
IMPACT
SENTIMENT
OCUP : Nasdaq
Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update
earnings
IMPACT
SENTIMENT
OCUP : Nasdaq
Ocuphire Pharma to Present at the Canaccord 43rd Annual Growth Conference and the H.C. Wainwright Ophthalmology Conference in August
conferences
IMPACT
SENTIMENT
OCUP : Nasdaq
Ocuphire to Present at American Society of Retina Specialists Annual Meeting and OIS Retina Innovation Summit
conferences
IMPACT
SENTIMENT
OCUP : Nasdaq
Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
IMPACT
SENTIMENT
OCUP : Nasdaq
Ocuphire Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Association’s Annual Conference
clinical trial
Stock OCUP logo
Ocuphire Pharma Inc
Nasdaq:OCUP

OCUP Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link

About OCUP

ocuphire is a new biopharmaceuticals company focused on developing and commercializing small molecule drugs for unmet medical needs in the ocular disease space. ocuphire’s lead drug candidate, nyxol eye drops, is aimed to treat patients with night vision disturbances (nvd), glaucoma and presbyopia (impaired near-term vision). ocuphire is in discussions with a prospective late stage ophthalmic drug program that could be developed in parallel. ocuphire's management team has over 100 years of drug development expertise across a diverse set of therapeutic areas including ophthalmology, orphan, cardio-metabolic, nephrology, oncology and respiratory.